Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: Response and survival

Steven D. Heys*, Keith N. Ogston, William G. Simpson, Leslie G. Walker, Andrew W. Hutcheon, Tarun K. Sarkar, Oleg Eremin

*Corresponding author for this work

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Seventy-seven patients with locally advanced breast cancer were treated with multimodality therapy comprising of six pulses of neo-adjuvant chemotherapy (doxorubicin, cyclophosphamide, vincristine and prednisolone) at 21-day intervals, followed by surgery (breast conservation or mastectomy) with appropriate axillary surgery, radiotherapy and adjuvant tamoxifen. The serum concentrations of acute phase proteins, C-reactive protein (CRP), α- 1-anti-trypsin, albumin and transferrin were measured in serum taken prior to commencement of treatment. Patients were followed up for a median of 31 months and their clinical and histological responses and overall survival recorded. Univariate analyses revealed that tumour stage (p=0.01), clinical lymph node status (p=0.02) and pre-treatment levels of serum albumin (p=0.002) and α-1-anti-trypsin (p=0.06) predicted overall survival. Using the Cox proportional hazards model reduced pre-treatment levels of serum albumin (p<0.00001), progressive lymph node involvement with tumour (p<0.005), and advancing tumour stage (p<0.01) were independent prognostic indicators for a poorer survival in patients with locally advanced breast cancer receiving neo-adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)589-594
Number of pages6
JournalInternational Journal of Oncology
Volume13
Issue number3
Publication statusPublished - 1 Sep 1998

Keywords

  • Acute phase proteins
  • Advanced breast cancer
  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: Response and survival'. Together they form a unique fingerprint.

  • Cite this